The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1839100 in healthy male subjects following oral administration of single rising doses.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
24
BI 1839100
Placebo matching BI 1839100
SOUSEIKAI Sumida Hospital
Tokyo, Sumida-ku, Japan
Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator
Time frame: up to 10 days
Area under the concentration-time curve of plasma BI 1839100 over the time interval from 0 extrapolated to infinity (AUC0-∞)
Time frame: up to 4 days
Maximum measured concentration of BI 1839100 in plasma (Cmax)
Time frame: up to 4 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.